跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT04817644
NCT04817644已完成1 期

A Trial Investigating Semaglutide and SNAC Concentrations in Breastmilk Following Administration of Multiple Doses of Oral Semaglutide in Healthy, Lactating Females

Novo Nordisk A/S2 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2021年9月10日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
14
试验地点
2
主要终点
Area under the semaglutide milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,milk)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Participants in the study, will receive the study drug once daily for 10 days in tablet form for oral (by mouth) intake. On day 1 to 5 the tablet will contain 3 mg semaglutide, and on day 6-10 the tablet will contain 7 mg semaglutide.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
Female
接受健康志愿者
是

入选标准

  • •Healthy, female subjects who have given birth at least 3 months prior to screening and who breastfeed (breastfeeding is defined by feeding the baby milk produced by the mother. Using a breast pump to collect milk and subsequently feeding it to the baby by bottle, is also defined as breastfeeding ) their infant to an extent, where the majority of the infant's total energy intake is from breastfeeding and sufficient milk is produced to fulfil the trial requirements, as judged by the investigator.
  • •Agree to abstain from breastfeeding their infant from first dose of oral semaglutide to the "End of trial" visit (total of 47 days) to avoid potentially exposing their child to semaglutide and SNAC.
  • •The breastfed infant is able to feed from a bottle (expenses related to alternative infant nutrition during trial participation will be covered by Novo Nordisk) prior to screening.
  • •Age above or equal to 18 years at the time of agreement to take part.
  • •Body mass index (BMI) between 20.0 and 32.4 kg/m^2 (both inclusive).

排除标准

  • •Female who is pregnant or intends to become pregnant or is of child-bearing potential and not using an effective contraceptive method.
  • •Glycated haemoglobin (HbA1c) greater than or equal to 6.5 % (48 mmol/mol) at screening.
  • •Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator.
  • •History (as declared by the subject or reported in the medical records) of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).
  • •Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (as declared by the subject or reported in the medical records).
  • •Presence or history (as declared by the subject or reported in the medical records) of malignant neoplasm within 5 years prior to the day of screening (basal or squamous cell skin cancer, or any carcinoma in-situ is allowed).
  • •Presence or history (as declared by the subject or reported in the medical records) of pancreatitis (acute or chronic).

研究组 & 干预措施

Oral semaglutide

Experimental

All participants will receive oral semaglutide once daily for a total of 10 days: 3 mg for 5 days followed by 7 mg for 5 days.

干预措施: Oral semaglutide (Drug)

结局指标

主要结局

Area under the semaglutide milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,milk)

时间窗: From 0 to 24 hours after the 10th dosing (day 10)

nmol\*h/L

Area under the salcaprozate sodium (SNAC) milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,milk)

时间窗: From 0 to 24 hours after the 10th dosing (day 10)

ng\*h/mL

次要结局

  • Maximum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Minimum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmin,sema,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum semaglutide milk concentration during a dosing interval after the 10th dosing (tmax,sema,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Estimated daily infant semaglutide dose(From 0 to 24 hours after the 10th dosing (day 10))
  • Relative daily infant semaglutide dose(From 0 to 24 hours after the 10th dosing (day 10))
  • Maximum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Average semaglutide milk concentration during a dosing interval after the 10th dosing (Cavg,sema,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Minimum SNAC milk concentration during a dosing interval after the 10th dosing (Cmin,SNAC,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum SNAC milk concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Average SNAC milk concentration during a dosing interval after the 10th dosing (Cavg,SNAC,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Maximum SNAC milk concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Estimated daily infant SNAC dose(From 0 to 24 hours after the 10th dosing (day 10))
  • Relative daily infant SNAC dose(From 0 to 24 hours after the 10th dosing (day 10))
  • Area under the SNAC metabolite E494 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Maximum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Minimum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmin,E506,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Average SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cavg,E494,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Maximum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Minimum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmin,E494,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum SNAC metabolite E494 milk concentration after the 10th dosing (tmax,E494,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Estimated daily infant SNAC metabolite E494 dose(From 0 to 24 hours after the 10th dosing (day 10))
  • Area under the SNAC metabolite E506 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Average SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cavg,E506,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum SNAC metabolite E506 milk concentration after the 10th dosing (tmax,E506,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Estimated daily infant SNAC metabolite E506 dose(From 0 to 24 hours after the 10th dosing (day 10))
  • Area under the SNAC metabolite E1245 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Average SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cavg,E1245,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Maximum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Minimum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmin,E1245,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum SNAC metabolite E1245 milk concentration after the 10th dosing (tmax,E1245,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Estimated daily infant SNAC metabolite E1245 dose(From 0 to 24 hours after the 10th dosing (day 10))
  • Area under the SNAC metabolite E1246 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Average SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cavg,E1246,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Minimum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmin,E1246,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum SNAC metabolite E1246 milk concentration in milk after the 10th dosing (tmax,E1246,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Estimated daily infant SNAC metabolite E1246 dose(From 0 to 24 hours after the 10th dosing (day 10))
  • Area under the SNAC metabolite E1247 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Average SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cavg,E1247,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Maximum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Minimum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmin,E1247,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum SNAC metabolite E1247 milk concentration after the 10th dosing (tmax,E1247,D10,milk)(From 0 to 24 hours after the 10th dosing (day 10))
  • Estimated daily infant SNAC metabolite E1247 dose(From 0 to 24 hours after the 10th dosing (day 10))
  • Area under the semaglutide plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (tmax,sema,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Area under the SNAC plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (tmax,E1246,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Area under the SNAC metabolite E1247 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Maximum SNAC plasma concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum SNAC plasma concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Area under the SNAC metabolite E494 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (tmax,E506,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (tmax,E494,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Area under the SNAC metabolite E506 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Area under the SNAC metabolite E1245 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (tmax,E1245,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Area under the SNAC metabolite E1246 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))
  • Time to maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (tmax,E1247,D10,plasma)(From 0 to 24 hours after the 10th dosing (day 10))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

已完成
3 期
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2
NCT02207374Novo Nordisk A/S601
已完成
1 期
A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy ParticipantsHealthy Participants
NCT05996874Novo Nordisk A/S121
已完成
1 期
Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy PeopleDiabetes Mellitus, Type 2
NCT04524832Novo Nordisk A/S290
已完成
不适用
SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in HungaryType 2 Diabetes
NCT06269120Novo Nordisk A/S243
已完成
3 期
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2
NCT02054897Novo Nordisk A/S388